Annovis Bio, Inc. Common Stock (ANVS)
3.7900
-0.0900 (-2.32%)
NYSE · Last Trade: Nov 22nd, 12:38 AM EST
Detailed Quote
| Previous Close | 3.880 |
|---|---|
| Open | 3.910 |
| Bid | 3.740 |
| Ask | 3.980 |
| Day's Range | 3.469 - 4.000 |
| 52 Week Range | 1.110 - 7.520 |
| Volume | 1,969,291 |
| Market Cap | 76.51M |
| PE Ratio (TTM) | -3.752 |
| EPS (TTM) | -1.0 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 2,925,856 |
Chart
About Annovis Bio, Inc. Common Stock (ANVS)
Annovis Bio Inc is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, particularly conditions like Alzheimer's disease and Parkinson's disease. The company is dedicated to advancing its proprietary platform designed to target and modulate underlying pathologies associated with these diseases. Annovis Bio aims to improve patient outcomes by researching and delivering potential treatments that can enhance cognitive function and overall quality of life for individuals affected by debilitating neurological disorders. Read More
News & Press Releases
On Thursday, there are stocks with unusual volume. Let's take a look.
Via Chartmill · November 20, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the stocks with an unusual volume in today's session.
Via Chartmill · November 18, 2025
The meeting with the FDA is scheduled for January 2026.
Via Stocktwits · November 18, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Type C Meeting to Advance Parkinson’s Disease Dementia Program
Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that the FDA has scheduled a Type C meeting in January 2026 to discuss the clinical pathway for buntanetap in Parkinson’s disease dementia. The Company also reaffirmed continued progress in its Phase 3 Alzheimer’s trial, which remains in full regulatory alignment on design, endpoints and patient population. CEO Maria Maccecchini said the meeting marks an important milestone for the PDD program, with Senior VP Cheng Fang noting that strong data across Alzheimer’s and Parkinson’s studies highlights buntanetap’s potential to address a major unmet need for cognitive decline in Parkinson’s patients.
Via Investor Brand Network · November 18, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END
Via FinancialNewsMedia · November 18, 2025
MarketNewsUpdates News Commentary
By MarketNewsUpdates.com · Via GlobeNewswire · November 18, 2025
MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type C meeting in January 2026 to discuss the Company's pathway for Parkinson's disease dementia (PDD). Annovis also reaffirmed that its ongoing Phase 3 AD clinical trial continues to progress with full regulatory alignment on study design, endpoints, and patient population.
By Annovis Bio Inc. · Via GlobeNewswire · November 18, 2025
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · November 17, 2025
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology.
Via Benzinga · November 17, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Via Chartmill · November 17, 2025
Via Benzinga · November 17, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports New Data Showing Buntanetap Reverses Cognitive Decline in Parkinson’s Patients With Amyloid Co-Pathology
Annovis Bio (NYSE: ANVS) released new findings from its Phase 3 early Parkinson’s disease study showing that buntanetap halted cognitive decline across all patients and delivered the strongest benefit in those with mild dementia and amyloid co-pathology, a group representing about 25% of the study population. These patients typically experience faster cognitive deterioration, but treatment with buntanetap reversed this decline and produced measurable reductions in pTau217, total tau and brain-derived tau—biomarkers associated with Alzheimer’s pathology. Annovis noted that the data reinforce its view that neurodegenerative diseases often overlap and require therapies capable of targeting multiple toxic proteins, positioning buntanetap as a potentially broad-acting treatment for cognitive impairment across Parkinson’s and Alzheimer’s disease biology.
Via Investor Brand Network · November 17, 2025
Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response
By Annovis Bio Inc. · Via GlobeNewswire · November 17, 2025
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will release its third quarter 2025 financial results before market open on Monday, Nov. 17, 2025, followed by a conference call at 8:30 a.m. ET to discuss corporate, financial, and operational updates.
Via Investor Brand Network · November 12, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, reported significant third quarter 2025 progress, led by full activation of all 84 sites in its pivotal Phase 3 Alzheimer’s study (NCT06709014) and steady enrollment across the U.S. The company also announced promising biomarker data from its Phase 2/3 Alzheimer’s trial showing strong reductions in inflammation and neurodegeneration, underscoring buntanetap’s disease-modifying potential. Recent achievements include transferring all patents to the new crystal form of buntanetap with IP protection through 2046, publishing supportive pharmacokinetic data, and appointing veteran finance executive Mark Guerin as CFO. “Every element is now aligned as we move toward our data readouts—the final step before an NDA submission,” said Maria Maccecchini, Ph.D., president and CEO.
Via Investor Brand Network · November 12, 2025
MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results.
By Annovis Bio Inc. · Via GlobeNewswire · November 12, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Completes Site Activation and Marks First Patient Completions in Pivotal Phase 3 Alzheimer’s Trial
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that all 84 U.S. sites for its pivotal Phase 3 trial in early Alzheimer’s disease are now fully activated and enrolling, with most already treating patients. The first group of participants has completed the 6-month treatment phase, keeping the company on schedule to deliver symptomatic data in the second half of 2026. CEO Maria Maccecchini said the study, now 25% complete, reflects strong execution and continued momentum toward bringing buntanetap to patients in need of effective therapies.
Via Investor Brand Network · November 6, 2025
All 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients
By Annovis Bio Inc. · Via GlobeNewswire · November 6, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces $3.4 Million Registered Direct Offering
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, entered definitive agreements for a registered direct offering of 1,670,732 shares of common stock at $2.05 per share, reflecting the Oct. 24 closing price. The $3.4 million offering, led by H.C. Wainwright & Co. as exclusive placement agent, includes participation from Chairman Michael Hoffman and CEO Dr. Maria Maccecchini. Closing is expected on or about Oct. 28, 2025, with proceeds earmarked for working capital and general corporate purposes.
Via Investor Brand Network · October 27, 2025
MALVERN, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements, with the participation of Michael Hoffman, the Chairman of the Company’s board of directors, and Dr. Maria Maccecchini, the Company’s Chief Executive Officer, for the purchase of an aggregate of 1,670,732 shares of its common stock at a purchase price of $2.05 per share, which was the closing price of the common stock on NYSE on October 24, 2025, in a registered direct offering. The closing of the offering is expected to occur on or about October 28, 2025, subject to the satisfaction of customary closing conditions.
By Annovis Bio Inc. · Via GlobeNewswire · October 27, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $6 Million Registered Direct Offering
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, closed its previously announced registered direct offering of 4 million shares of common stock (or pre-funded warrants) at $1.50 per share. H.C. Wainwright & Co. served as exclusive placement agent. Gross proceeds totaled approximately $6 million before fees and expenses, with net proceeds intended for working capital and general corporate purposes.
Via Investor Brand Network · October 16, 2025
MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announced registered direct offering for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant in lieu thereof).
By Annovis Bio Inc. · Via GlobeNewswire · October 15, 2025
Via Benzinga · October 10, 2025
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · October 10, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · October 10, 2025